Results 161 to 170 of about 94,936 (269)

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast ...
Xiaopei Dong, Fan Li, Yang Yuan, Hua Song, Yingzhe Wang, Yi Hao, Yinping Dong, Tao Wang, Li Bian, Shaohua Zhang, Jianbin Li   +10 more
wiley   +1 more source

Multidisciplinary Management of Severe Taxane-Induced Nail Toxicity in a Breast Cancer Patient. [PDF]

Cancer Manag Res
Sauer N, Kowalczuk M, Arkada A, Calik J.
europepmc   +1 more source

Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Effective treatment options remain limited for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), including patients who have progressed after platinum‐based chemotherapy and systemic‐therapy‐naïve patients.
Jinguan Lin, Song Qu, Kunyu Yang, Tao Zhang, Yuansong Bai, Jian Wu, Yanjing Huang, Meiyu Fang, Xianling Liu, Xiaoming Huang, Nianyong Chen, Zhendong Li, Weidong Li, Songnan Zhang, Shurong Zhang, Guangyuan Hu, Yan Sun, Xiaohong Chen, Yanyan Liu, Shanghua Jing, Liangfang Shen, Zhiwei Chang, Liangzhi Xie, Wenlin Gai, Yan Wang, Xinyue Chen, Dongfang Liu, Ye Guo   +27 more
wiley   +1 more source

Targeting KRAS^G12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies. [PDF]

Front Oncol
Piekarz J, Picheta N, Pobideł J, Gierulska N, Kłodnicka K, Januszewski J, Szklener K, Skórzewska M.   +7 more
europepmc   +1 more source

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges.
Marija Nikolovska, Radoslav Stojchevski, Aleksandar Eftimov, Mitko Mladenov, Dimiter Avtanski, Nikola Hadzi‐Petrushev   +5 more
wiley   +1 more source

Concurrent Ocular and Dermatologic Toxicities Associated With Docetaxel Chemotherapy. [PDF]

J Adv Pract Oncol
Wittig JA, Grabowski J, Villani SC, Kono SA, Friedrich TJ.   +4 more
europepmc   +1 more source

Efficacy and Safety of Initial Low‐Dose, Extended‐Interval Nivolumab Monotherapy in a 91‐Year‐Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT The incidence of non‐small cell lung cancer (NSCLC) increases with age, with approximately half of the cases diagnosed in individuals aged 70 and older. In numerous clinical trials, immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in treating NSCLC without driver gene mutations.
Dan Kou, Xiang Yan, Qi Huang, Jingye Zhong, Qiongcheng Chen, Tao Zhao, Xianhua Xu   +6 more
wiley   +1 more source

Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial. [PDF]

Breast
Penault-Llorca F, Lusque A, Filleron T, Tran K, Du L, Baehner R, Dalenc F, Lacroix-Triki M, Bachelot T, Andre F, Boucher P, Lemonnier J, Symmans WF.   +12 more
europepmc   +1 more source

A POLE P286R‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Hepatoid adenocarcinoma of the lung (HAL) is a rare form of lung cancer with histological and morphological properties of hepatocellular carcinoma, characterized by an aggressive course of the disease and unfavorable prognosis. Given the rarity of the pathology and the lack of unambiguous therapeutic protocols, descriptions of ...
Aleksey Chernev, Alina Kaurtseva, Ruslan Abasov, Rafael Enikeev, Nina Gegelia, Gulnara Abdrakova, Natalia Usman, Alexander Druy, Grigory Raskin   +8 more
wiley   +1 more source

Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study. [PDF]

Int J Urol
Kamiyama M, Izumi K, Mitsui T, Shima T, Kato Y, Mita K, Okamura T, Inoue S, Hoshi S, Tanaka N, Yoshio Y, Tatarano S, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A.   +18 more
europepmc   +1 more source